Hypercalcemia syndrome: Diagnostic search and approaches to therapy

1. Flowers KC, Shipman KE, Shipman AR, Gitoees NLJ. Investigative algorithms for disorders causing hypercalcaemia and hypocalcaemia: A narrative review. J Lab Precis Med. 2024;9:27.

https://dx.doi.org/10.21037

2. Renaghan ADM, Rosner M. Hypercalcemia: Etiology and management. Nephrol Dial Transpl. 2018;33(4):549–51.

https://doi.org/10.1093/ndt/gfy054

3. Мокрышева Н.Г., Еремкина А.К., Мирная С.С., Крупинова Ю.А., Воронкова И.А., Ким И.В. с соавт. Клинические рекомендации по первичному гиперпаратиреозу, краткая версия. Проблемы эндокринологии. 2021;67(4):94–124. (Mokrysheva NG, Eremkina AK, Mirnaya SS, Krupinova YuA, Voronkova IA, Kim IV et al. The clinical practice guidelines for primary hyperparathyroidism, short version. Problemy endokrinologii = Problems of Endocrinology. 2021;67(4):94–124 (In Russ.)).

EDN: GKEEJB. https://doi.org/10.14341/probl12801

4. Terrell K, Choi S, Choi S. Calcium’s role and signaling in aging muscle, cellular senescence, and mineral interactions. Int J Mol Sci. 2023;24(23):17034.

PMID: 38069357. PMCID: PMC10706910. https://doi.org/10.3390/ijms242317034

5. Thillainadesan S, Twigg SM, Perera N. Prevalence, causes and associated mortality of hypercalcaemia in modern hospital care. Intern Med J. 2022;52(9):1596–1601.

PMID: 34092015. https://doi.org/10.1111/imj.15402

6. Venyo AK-G, Adaramod O. Hypercalcemia: A review and update. J Urol Neph St. 2023;4(1):397–422.

https://doi.org/10.32474/JUNS.2023.04.000179

7. Воронцова М.В., Кулебякин К.Ю., Маказан Н.В., Созаева Л.С., Тюрин-Кузьмин П.А. Паратиреоидный гормон в регуляции процессов роста и резорбции кости в норме и патологии. Вестник Российской академии медицинских наук. 2021;76(5):506–517. (Vorontsova MV, Kulebyakin KYu, Makazan NV, Sozaeva LS, Tyurin-Kuzmin PA. Parathyroid hormone in the regulation of bone growth and resorption in health and disease. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2021;76(5):506–517 (In Russ.)).

EDN: EJLRBV. https://doi.org/https://doi.org/10.15690/vramn1440

8. Martin TJ. PTH1R actions on bone using the cAMP/protein kinase a pathway. Front Endocrinol (Lausanne). 2022;12:833221.

PMID: 35126319. PMCID: PMC8807523. https://doi.org/10.3389/fendo.2021.833221

9. Matikainen N, Pekkarinen T, Ryhänen EM, Schalin-Jäntti C. Physiology of calcium homeostasis: An overview. Endocrinol Metab Clin North Am. 2021;50(4):575–90.

PMID: 34774235. https://doi.org/10.1016/j.ecl.2021.07.005

10. Kuzma M, Jackuliak P, Killinger Z, Payer J. Parathyroid hormone-related changes of bone structure. Physiol Res. 2021;70(Suppl 1):S3–S11.

PMID: 34918524. PMCID: PMC8884379. https://doi.org/10.33549/physiolres.934779

11. Мокрышева Н.Г., Крупинова Ю.А., Ковалева Е.В. Паратиреоидный гормон и подобные ему пептиды. Обзор литературы. Вестник Российской академии медицинских наук. 2019;74(2):136–144. (Mokrysheva NG, Krupinova YuA, Kovaleva EV. The parathyroid hormone and peptides like it. Literature review. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2019;74(2):136–144 (In Russ.)).

EDN: EFXNKA. https://doi.org/10.15690/vramn1104

12. Gianella F, Hsia CC, Sakhaee K. The role of vitamin D in sarcoidosis. Fac Rev. 2020;9:14.

PMID: 33659946. PMCID: PMC7886067. https://doi.org/10.12703/b/9-14

13. Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium-parathyroid hormone-vitamin D axis. Front Horm Res. 2018;50:1–13.

PMID: 29597231. https://doi.org/10.1159/000486060

14. Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018;14(2):115–25.

PMID: 28885621. PMCID: PMC6037987. https://doi.org/10.1038/nrendo.2017.104

15. Fleet JS. The role of vitamin D in the endocrinology controlling calcium homeostasis. Mol Cell Endocrinol. 2017;453:36–45.

PMID: 28400273. PMCID: PMC5529228. https://doi.org/10.1016/j.mce.2017.04.008

16. Агранович Н.В., Пилипович Л.А., Алботова Л.В., Классова А.Т. К вопросу о дефиците витамина D при хронической болезни почек. Литературный обзор. Нефрология. 2019;23(3):21–28. (Agranovich NV, Pilipovich LA, Albotova LV, Klassova AT. About the question of vitamin D deficiency in chronic kidney disease. Literature review. Nefrologiya = Nephrology (Saint Petersburg). 2019;23(3):21–28 (In Russ.)).

EDN: ZEOOGQ. https://doi.org/10.24884/1561-6274-2019-23-3-21-28

17. Bikle D, Christakos S. New aspects of vitamin D metabolism and action – addressing the skin as source and target. Nat Rev Endocrinol. 2020;16(4):234–52.

PMID: 32029884. https://doi.org/10.1038/s41574-019-0312-5

18. Pike JW, Christakos S. Biology and mechanisms of action of the vitamin D hormone. Endocrinol Metab Clin North Am. 2017;46(4):815–43.

PMID: 29080638. PMCID: PMC5762112. https://doi.org/10.1016/j.ecl.2017.07.001

19. Khammissa RAG, Fourie J, Motswaledi MH, Ballyram R, Lemmer J, Feller L. The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health. Biomed Res Int. 2018;2018:9276380.

PMID: 29951549. PMCID: PMC5987305. https://doi.org/10.1155/2018/9276380

20. Felsenfeld AJ, Levine BS. Calcitonin, the forgotten hormone: Does it deserve to be forgotten? Clin Kidney J. 2015;8(2):180–87.

PMID: 25815174. PMCID: PMC4370311. https://doi.org/10.1093/ckj/sfv011

21. Goldner W. Cancer-related hypercalcemia. J Oncol Pract. 2016;12(5):426–32.

PMID: 27170690. https://doi.org/10.1200/jop.2016.011155

22. Bollerslev J, Pretorius M, Heck A. Parathyroid hormone independent hypercalcemia in adults. Best Pract Res Clin Endocrinol Metab. 2018;32(5):621–38.

PMID: 30449545. https://doi.org/10.1016/j.beem.2018.06.005

23. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet Lond Engl. 2018;391(10116):168–78.

PMID: 28923463. https://doi.org/10.1016/S0140-6736(17)31430-7

24. Крупинова Ю.А., Алмасханова А.А., Еремкина А.К., Бибик Е.Е., Васильев Е.В., Мокрышева Н.Г. Серия клинических случаев синдрома семейной гипокальциурической гиперкальциемии. Проблемы эндокринологии. 2020;66(5):61–69. (Krupinova YuA, Almaskhanova AA, Eremkina AK, Bibik EE, Vasilyev EV, Mokrysheva NG. A series of clinical cases of familial hypocalciuric hypercalcemia syndrome. Problemy endokrinologii = Problems of Endocrinology. 2020;66(5):61–69 (In Russ.)).

EDN: ODBBSK. https://doi.org/10.14341/probl12537

25. Fuleihan GE-H, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T et al. Treatment of hypercalcemia of malignancy in adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2023;108(3):507–28.

PMID: 36545746. https://doi.org/10.1210/clinem/dgac621

26. Guise TA, Wysolmerski JJ. Cancer-associated hypercalcemia. N Engl J Med. 2022;386(15):1443–51.

PMID: 35417639. https://doi.org/10.1056/nejmcp2113128

27. Almuradova E, Cicin I. Cancer-related hypercalcemia and potential treatments. Front Endocrinol (Lausanne). 2023;14:1039490.

PMID: 37033238. PMCID: PMC10073684. https://doi.org/10.3389/fendo.2023.1039490

28. Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R. Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med. 2003;115(2):115–21.

PMID: 12893397. https://doi.org/10.1016/s0002-9343(03)00310-3

29. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and cancer: Differential diagnosis and treatment. CA Cancer J Clin. 2018;68(5):377–86.

PMID: 30240520. https://doi.org/10.3322/caac.21489

30. Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015;11:1779–88.

PMID: 26675713. PMCID: PMC4675637. https://doi.org/10.2147/TCRM.S83681

31. Shi S, Zhang L, Yu Y, Wang C, Li J. Acromegaly and non-parathyroid hormone-dependent hypercalcemia: A case report and literature review. BMC Endocr Disord. 2021;21(1):90.

PMID: 33933067. PMCID: PMC8088721. https://doi.org/10.1186/s12902-021-00756-z

32. Kaur K, Batra N, Kadian K, Sridharan K. Hypercalcaemia as the initial presentation of Graves’ disease. BMJ Case Rep. 2022;15(8):e251454.

PMID: 35985738. PMCID: PMC9396191. https://doi.org/10.1136/bcr-2022-251454

33. Turner J, Haider A, Barghouthi N, Symczyk O. PTH-independent hypercalcemia in undiagnosed adrenal insufficiency. Journal of the Endocrine Society. 2021;5(Supplement_1):A154–A155.

https://doi.org/10.1210/jendso/bvab048.312

34. Taylor PN, Davies JS. A review of the growing risk of vitamin D toxicity from inappropriate practice. Br J Clin Pharmacol. 2018;84(6):1121–27.

PMID: 29498758. PMCID: PMC5980613. https://doi.org/10.1111/bcp.13573

35. Lim K, Thadhani R. Vitamin D toxicity. J Bras Nefrol. 2020;42(2):238–44.

PMID: 32255467. PMCID: PMC7427646. https://doi.org/10.1590/2175-8239-jbn-2019-0192

36. Minisola S, Pepe J, Piemonte S, Cipriani C. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723.

PMID: 26037642. https://doi.org/10.1136/bmj.h2723

37. Bandeira F, Cusano NE, Silva BC, Cassibba S, Almeida CB, Machado VCC, Bilezikian JP. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2014;58(5):553–61.

PMID: 25166047. PMCID: PMC4315357. https://doi.org/10.1590/0004-2730000003381

38. Ильичева Е.А., Берсенев Г.А., Григорьев Е.Г. Случай поздней диагностики гигантской аденомы околощитовидной железы в сочетании с фиброзно-кистозным остеитом и бурой опухолью верхней челюсти: клиническое наблюдение. Проблемы эндокринологии. 2021;67(2):49–56. (Ilyicheva EA, Bersenev GA, Griroryev EG. The case of late diagnosis of giant parathyroid adenoma in combination with fibrocystic osteitis and brown tumor of the upper jaw: A case report. Problemy endokrinologii = Problems of Endocrinology. 2021;67(2):49–56 (In Russ.)).

PMID: 34004103. PMCID: PMC8926140. EDN: UBKUEQ. https://doi.org/10.14341/probl12713

39. Мокрышева Н.Г., Еремкина А.К., Мирная С.С., Володичева В.Л., Паневин Т.С., Мельниченко Г.А. Патологические изменения в суставах и мышцах при первичном гиперпаратиреозе. Остеопороз и остеопатии. 2018;21(4):10–18. (Mokrysheva NG, Eremkina AK, Mirnaya SS, Volodicheva VL, Panevin TS, Melnichenko GA. Joint and muscle involvement in primary hyperparathyroidism. Osteoporoz i osteopatii = Osteoporosis and Osteopathy. 2018;21(4):10–18 (In Russ.)).

EDN: CGMCPI. https://doi.org/10.14341/osteo9783

40. Walker MD, Shane E. Hypercalcemia: A review. JAMA. 2022;328(16):1624–36.

PMID: 36282253. https://doi.org/10.1001/jama.2022.18331

41. Basok AB, Rogachev B, Haviv YS, Vorobiov M. Treatment of extreme hypercalcaemia: The role of haemodialysis. BMJ Case Rep. 2018;2018:bcr2017223772.

PMID: 29866671. PMCID: PMC5990060. https://doi.org/10.1136/bcr-2017-223772.bcr2017223772

42. Tebben PJ, Singh RJ, Kumar R. Vitamin D-mediated hypercalcemia: Mechanisms, diagnosis, and treatment. Endocr Rev. 2016;37(5):521–47.

PMID: 27588937. PMCID: PMC5045493. https://doi.org/10.1210/er.2016-1070

43. Елфимова А.Р., Еремкина А.К., Реброва О.Ю., Ковалева Е.В., Мокрышева Н.Г. Прогнозирование развития гипокальциемии у пациентов с ПГПТ в 1–3 сутки после паратиреоидэктомии. Эндокринная хирургия. 2023;17(3):50–60. (Elfimova AR, Eremkina AK, Rebrova OYu, Kovaleva EV, Mokrysheva NG. Prediction of the development of hypocalcemia in primary hyperparathyroidism patients 1-3 days after radical parathyroidectomy. Endokrinnaya khirurgiya = Endocrine Surgery. 2023;17(3):50–60 (In Russ.)).

EDN: DJKMHC. https://doi.org/10.14341/serg12824

44. Bilezikian JP. Hypoparathyroidism. J Clin Endocrinol Metab. 2020;105(6):1722–36.

PMID: 32322899. PMCID: PMC7176479. https://doi.org/10.1210/clinem/dgaa113

45. Liu C, Tang L, Goel P, Chambers T, Kokot N, Sinha U, Maceri D. A practical mathematic method to predict and manage hypocalcemia after parathyroidectomy and thyroidectomy. Ann Otol Rhinol Laryngol. 2020;129(1):70–77.

PMID: 31510765. https://doi.org/10.1177/0003489419876291

46. Schneider DF, Mazeh H, Chen H, Sippel RS. Predictors of recurrence in primary hyperparathyroidism: An analysis of 1386 cases. Ann Surg. 2014;259(3):563–68.

PMID: 24263316. PMCID: PMC4250051. https://doi.org/10.1097/sla.0000000000000207

47. Carsote M, Nistor C. Forestalling hungry bone syndrome after parathyroidectomy in patients with primary and renal hyperparathyroidism. Diagnostics (Basel). 2023;13(11):1953.

PMID: 37296804. PMCID: PMC10252569. https://doi.org/10.3390/diagnostics13111953

48. Lorenz FJ, Goldenberg D. Hypocalcemia after parathyroidectomy in patients taking proton pump inhibitors. Am J Otolaryngol. 2023;44(2):103761.

PMID: 36586320. PMCID: PMC10033382. https://doi.org/10.1016/j.amjoto.2022.103761

49. Jain N, Reilly RF. Hungry bone syndrome. Curr Opin Nephrol Hypertens. 2017;26(4):250–55.

PMID: 28375869. https://doi.org/10.1097/mnh.0000000000000327

50. Fackelmayer OJ, Wu JX, Yeh MW. Endocrine surgery: Management of postoperative complications following endocrine surgery of the neck. Surg Clin North Am. 2021;101(5):767–84.

PMID: 34537142. https://doi.org/10.1016/j.suc.2021.05.019

51. Acharya R, Kopczynska M, Goodmaker C, Mukherjee A, Doran H. Vitamin D repletion in primary hyperparathyroid patients undergoing parathyroidectomy leads to reduced symptomatic hypocalcaemia and reduced length of stay: A retrospective cohort study. Ann R Coll Surg Engl. 2022;104(1):41–47.

PMID: 34727512. PMCID: PMC10335014. https://doi.org/10.1308/rcsann.2021.0078

52. Mulkareddy V, Bhalla V, Upadhye S, Siddam P. The diagnostic dilemma of sarcoidosis: A case of acute hypercalcemia. Cureus. 2020;11;12(9):e10399.

PMID: 33062519. PMCID: PMC7549992. https://doi.org/10.7759/cureus.10399